Sk (for quartiles 4 vs. 1: OR = 0.69, 95 CI: 0.46, 1.02; Ptrend = 0.011) (Table four). No effect modification of genetic variation in MPO G463A on nonaggressive prostate cancer risk was observed for n-3 and n-6 PUFAs (Web Table 2) or on any prostate cancer threat for trans-fatty acids (Web Table three). However, the polymorphism considerably modified the associations of quite a few long-chain and very-long-chain n-3 and n-6 PUFAs with aggressive prostate cancer danger (Table five). For n-3 PUFAs, the MPO GA/AA versus GG genotypes had been associated with a practically 2-fold boost in aggressive prostate cancer danger amongst guys with low (quartile 1) EPA + DHA (OR = 1.97, 95 CI: 1.07, three.63). Among males using the MPO GG genotypes, a good, however nonsignificant, associationAm J Epidemiol. 2013;177(ten):1106?Am J Epidemiol. 2013;177(10):1106?Table three. Multivariable-adjusteda Association of Serum n-3 and n-6 Polyunsaturated Fatty Acids With Nonaggressive Prostate Cancerb Danger in the Carotene and Retinol Efficacy Trial, 1985?Quartile 1 Fatty Acids No. of Situations No. of Controls OR 95 CI No. of Instances Quartile 2 No. of Controls OR 95 CI No. of Cases Quartile three No. of Controls OR 95 CI No. of Circumstances Quartile 4 No. of Controls OR 95 CI Ptrendn-3 PUFAs -Linolenic acid Eicosatrienoic acid Eicosapentaenoic acid Docosapentaenoic acid Docosahexaenoic acid EPA + DHA Total n-3 n-6 PUFAs Linoleic acid -Linolenic acid Eicosadienoic acid Dihomo–linolenic acid Arachidonic acid Docosadienoic acid Docosatetraenoic acid Total n-6 99 92 110 101 99 87 95 89 349 350 350 349 350 350 350 350 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Referent Referent Referent Referent Referent Referent Referent Referent 88 90 87 104 76 114 98 105 350 349 349 350 349 349 349 349 0.89 0.93 0.79 1.01 0.78 1.33 1.03 1.21 0.64, 1.23 0.67, 1.29 0.57, 1.09 0.74, 1.38 0.56, 1.09 0.97, 1.83 0.74, 1.42 0.88, 1.68 90 91 80 94 85 79 92 72 350 349 350 349 349 349 349 349 0.91 0.65, 1.26 0.89 0.64, 1.25 0.71 0.51, 0.99 0.92 0.66, 1.27 0.89 0.64, 1.24 0.92 0.66, 1.30 0.97 0.70, 1.34 0.84 0.59, 1.19 91 95 91 69 108 88 83 102 349 349 349 350 350 350 350 350 0.93 0.96 0.83 0.66 1.16 1.04 0.89 1.21 0.67, 1.30 0.69, 1.34 0.60, 1.14 0.47, 0.95 0.84, 1.60 0.74, 1.46 0.63, 1.24 0.87, 1.68 0.72 0.78 0.18 0.024 0.32 0.61 0.44 0.66 84 85 77 96 88 78 93 350 350 350 349 349 350 350 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Referent Referent Referent Referent Referent Referent Referent 114 88 97 95 93 98 84 349 349 349 350 350 349 349 1.36 1.07 1.24 0.97 1.05 1.26 0.90 0.99, 1.88 0.77, 1.50 0.89, 1.74 0.70, 1.33 0.75, 1.46 0.90, 1.77 0.64, 1.25 88 98 104 88 99 102 103 349 350 350 349 349 350 349 1.06 0.75, 1.48 1.18 0.Price of 191347-94-1 84, 1.Buy19393-83-0 64 1.PMID:26446225 28 0.92, 1.79 0.88 0.63, 1.22 1.13 0.81, 1.58 1.31 0.93, 1.83 1.09 0.79, 1.51 82 96 90 89 88 90 88 350 349 349 350 350 349 350 0.99 1.15 1.07 0.89 1.00 1.14 0.92 0.70, 1.41 0.83, 1.61 0.75, 1.52 0.64, 1.24 0.70, 1.41 0.80, 1.63 0.66, 1.30 0.59 0.34 0.70 0.41 0.90 0.45 0.Serum Phospholipid Fatty Acids and Prostate CancerAbbreviations: CARET, Carotene and Retinol Efficacy Trial; CI, self-confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; OR, odds ratio; PUFA, polyunsaturated fatty acid. a Multivariate adjustment for age at enrollment (continuous), race (white, black, other people), CARET randomization assignment (retinol plus -carotene, placebo), family history of prostate cancer in first-degree relatives (yes, no), alcohol consumption (nondrinker, below median, at or above median, unknown), smoking status.